Opportunity Information: Apply for W81XWH 22 PCARP TRPA
The DoD Pancreatic Cancer, Translational Research Partnership Award (FY22 PCARP TRPA; Funding Opportunity Number W81XWH-22-PCARP-TRPA) is a Department of Defense funding opportunity managed by the US Army Medical Research Acquisition Activity (USAMRAA) that is designed to push pancreatic cancer research ideas closer to real-world clinical use. The main purpose is to fund tightly integrated collaborations that can move promising concepts toward applications in prevention, detection, diagnosis, prognosis, treatment, or survivorship. The program is explicitly focused on translational work, meaning projects should not stay purely in the lab or purely in the clinic; they should actively connect the two in a way that speeds progress toward patient impact, with relevance to Service Members, Veterans, other military beneficiaries, and the broader public.
A defining requirement of this award is that it must be led by two independent Principal Investigators who function as equal intellectual partners: one must be a research scientist and the other must be a clinician investigator. The partnership is not meant to be superficial or transactional. Applications are expected to show that both investigators had meaningful, roughly equal input into the project design and that the work truly depends on the distinct expertise of each partner. The announcement makes it clear that a project where the clinician only provides patient access or supplies tissue samples does not fit the intent; the clinician partner needs to be engaged in shaping the scientific questions, study design, interpretation, and the translational path forward. While at least one partner must bring expertise in pancreatic cancer research or pancreatic cancer patient care, the program also encourages bringing in experts from outside the pancreatic cancer field, especially when that outside expertise can unlock new approaches. Projects that use convergence science style partnerships, where different disciplines are intentionally integrated to solve a hard problem, are strongly encouraged.
The program emphasizes several core review features. First is Partnership: the collaboration should be essential, with success hinging on the unique skills and contributions of both PIs rather than parallel work that could be done separately. Second is Translation: the proposal should show a reciprocal, two-way flow of ideas and information between basic and clinical science. In practice, that can include correlative studies tied to patient outcomes, use or creation of annotated biorepositories, and analyses that deliberately leverage clinical data to fill knowledge gaps, validate key findings, extend potentially transformative results, or explore new observations arising from patient care. Third is Impact: projects should have credible potential to significantly influence pancreatic cancer research and/or patient care and to accelerate movement of an idea into a clinical application. Fourth is Feasibility: investigators must show they can actually execute the work, including access to needed specimens, datasets, and/or interventions. Finally, Preliminary Data is required: applicants must include relevant published or unpublished results from the PIs or named collaborators, and they must provide data supporting the feasibility of the hypothesis and approach. Importantly, the feasibility data do not have to come from pancreatic cancer specifically; the program recognizes that strong translational ideas can be motivated by laboratory discoveries, population studies, or clinical firsthand observations and anecdotal signals.
In terms of the kinds of studies supported, the award is not positioned to fully fund large-scale clinical trials. Instead, it allows and expects more targeted translational efforts such as retrospective tissue analyses, correlative clinical studies, and small pilot clinical trials. The overall expectation is that a funded team will use the partnership to move faster and more convincingly toward a clinical application than either investigator could accomplish alone, while maintaining continuous feedback between clinical realities and mechanistic or technological development in the lab.
Operationally, the mechanism supports cooperative agreements and grants under CFDA 12.420, with eligibility listed as unrestricted (open broadly to applicant entity types, subject to any specific notes in the full solicitation). The award requires designation of an Initiating PI, who handles most of the administrative submission responsibilities, and a Partnering PI. Even though the Initiating PI coordinates submission, both PIs are expected to contribute substantially to core proposal elements such as the Project Narrative and Statement of Work. If selected for funding, each PI is named on an individual award within the recipient organization, reinforcing the two-PI structure. For multi-institution collaborations, applicants must also include clear interaction plans covering communication, coordination, progress and results sharing, and data transfer, and they must provide an intellectual property plan to proactively resolve potential IP or material transfer issues that could otherwise slow cooperation.
Key administrative details from the posted opportunity include a posting (creation) date of April 25, 2022, an original closing date of October 6, 2022, and an expectation of approximately four awards. The listing shows an award ceiling of 0, which typically indicates that the ceiling is not specified in the summary field and that applicants should rely on the full announcement for budget limits and guidance.Apply for W81XWH 22 PCARP TRPA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Pancreatic Cancer, Translational Research Partnership Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Apr 25, 2022.
- Applicants must submit their applications by Oct 06, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
DoD Pancreatic Cancer, Translational Research Partnership Award (FY22 PCARP TRPA) FAQs
1. What is the FY22 PCARP Translational Research Partnership Award (TRPA)?
The FY22 PCARP Translational Research Partnership Award (TRPA) is a Department of Defense (DoD) funding opportunity (Funding Opportunity Number W81XWH-22-PCARP-TRPA) managed by the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to push promising pancreatic cancer research ideas closer to real-world clinical use by supporting tightly integrated, two-PI translational partnerships.
2. What is the main purpose of this award?
The purpose is to fund collaborations that can move promising concepts toward clinical applications in pancreatic cancer prevention, detection, diagnosis, prognosis, treatment, or survivorship. The award is explicitly focused on translation, meaning the work should connect laboratory research and clinical reality in a way that accelerates patient impact.
3. What does "translational" mean in the context of this program?
In this program, "translational" means the project should not remain purely basic (lab-only) or purely clinical (clinic-only). Instead, the proposal should demonstrate an active, two-way connection between basic and clinical science that speeds progress toward a clinical application, with ongoing feedback between the clinic and the lab.
4. Who is this program intended to benefit?
The opportunity emphasizes relevance to Service Members, Veterans, other military beneficiaries, and the broader public.
5. Is a two-Principal Investigator (two-PI) structure required?
Yes. A defining requirement is that the project must be led by two independent Principal Investigators who function as equal intellectual partners.
6. What are the required roles for the two PIs?
One PI must be a research scientist and the other must be a clinician investigator. They are expected to operate as equal intellectual partners rather than having a superficial or transactional collaboration.
7. What does the program mean by "equal intellectual partners"?
The application is expected to show that both investigators had meaningful, roughly equal input into the project design and that the project genuinely depends on the distinct expertise of each partner. The clinician partner must be engaged in shaping the scientific questions, study design, interpretation, and translational path forward.
8. Can the clinician partner participate mainly by providing patient access or tissue samples?
No. The announcement explicitly states that a project where the clinician only provides patient access or supplies tissue samples does not fit the intent of the award.
9. Does at least one PI need pancreatic cancer expertise?
Yes. At least one partner must bring expertise in pancreatic cancer research or pancreatic cancer patient care.
10. Can the partnership include experts outside the pancreatic cancer field?
Yes. The program encourages bringing in experts from outside pancreatic cancer, especially when outside expertise can unlock new approaches. Convergence science style partnerships that intentionally integrate different disciplines are strongly encouraged.
11. What are the key features reviewers emphasize?
The program highlights core review features including Partnership, Translation, Impact, Feasibility, and Preliminary Data.
12. What does "Partnership" mean as a review feature?
Partnership means the collaboration should be essential to success. Reviewers expect that the project hinges on the unique skills and contributions of both PIs, rather than parallel work that could be done separately.
13. What does "Translation" mean as a review feature?
Translation means there should be a reciprocal, two-way flow of ideas and information between basic and clinical science. Examples described in the opportunity include correlative studies tied to patient outcomes, use or creation of annotated biorepositories, and analyses that deliberately leverage clinical data to fill knowledge gaps, validate findings, extend transformative results, or explore new clinical observations.
14. What does "Impact" mean for this award?
Impact refers to the credible potential for the project to significantly influence pancreatic cancer research and/or patient care and to accelerate movement of an idea into a clinical application.
15. What does "Feasibility" mean for this award?
Feasibility means investigators must show they can execute the work, including access to needed specimens, datasets, and/or interventions.
16. Is preliminary data required?
Yes. Relevant published or unpublished results from the PIs or named collaborators are required, and the application must include data supporting the feasibility of the hypothesis and approach.
17. Must preliminary data be in pancreatic cancer specifically?
No. The opportunity notes that feasibility data do not have to come from pancreatic cancer. Strong translational ideas may be motivated by laboratory discoveries, population studies, or clinical firsthand observations and anecdotal signals.
18. What types of studies are supported by this award?
The award supports targeted translational efforts such as retrospective tissue analyses, correlative clinical studies, and small pilot clinical trials, with an overall emphasis on accelerating progress toward clinical application through a tightly integrated partnership.
19. Does this award fully fund large-scale clinical trials?
No. The award is not positioned to fully fund large-scale clinical trials. It focuses instead on more targeted translational efforts, including small pilot clinical trials.
20. What kind of funding mechanism is used?
The mechanism supports cooperative agreements and grants, and it is listed under CFDA 12.420.
21. What is meant by "Initiating PI" and "Partnering PI"?
The award requires designation of an Initiating PI, who handles most administrative submission responsibilities, and a Partnering PI. Even though the Initiating PI coordinates submission, both PIs are expected to contribute substantially to key proposal elements such as the Project Narrative and Statement of Work.
22. If selected for funding, how are awards issued with two PIs?
If selected, each PI is named on an individual award within the recipient organization, reinforcing the two-PI structure.
23. What additional requirements apply to multi-institution collaborations?
Multi-institution collaborations must include clear interaction plans covering communication, coordination, progress and results sharing, and data transfer. They must also provide an intellectual property plan to proactively address potential IP or material transfer issues that could slow cooperation.
24. What is known about eligibility for this opportunity?
Eligibility is listed as unrestricted (open broadly to applicant entity types), subject to any specific notes in the full solicitation.
25. When was this opportunity posted, and what was the original closing date?
The posted (creation) date is April 25, 2022, and the original closing date is October 6, 2022.
26. How many awards were expected to be made?
The opportunity indicates an expectation of approximately four awards.
27. What is the award ceiling (maximum budget) for this opportunity?
The listing shows an award ceiling of 0, which typically indicates the ceiling is not specified in the summary field. Applicants are expected to rely on the full announcement for budget limits and guidance.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Low Income Taxpayer Clinic
Previous opportunity: Academy for Women Entrepreneurs 3.0
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 22 PCARP TRPA
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 22 PCARP TRPA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Pancreatic Cancer, Idea Development Award Apply for W81XWH 22 PCARP IDA Funding Number: W81XWH 22 PCARP IDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Fiscal Year (FY) 2023 Young Investigator Program Apply for N00014 22 S F007 Funding Number: N00014 22 S F007 Agency: Department of Defense, Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: $510,000 |
| In Situ Measurements of Physical Forces, Geotechnical and Biological Parameters in Coastal and Estuarine Systems, Galveston District Apply for W81EWF 22 SOI 0015 Funding Number: W81EWF 22 SOI 0015 Agency: Department of Defense, Engineer Research and Development Center Category: Science and Technology and other Research and Development Funding Amount: $930,000 |
| DOE Traineeship in Computational High Energy Physics Apply for DE FOA 0002743 Funding Number: DE FOA 0002743 Agency: Department of Energy - Office of Science, Office of Science Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Libby and Bonneville Dams Maximum Precipitation Studies Apply for W81EWF 22 SOI 0006 Funding Number: W81EWF 22 SOI 0006 Agency: Department of Defense, Engineer Research and Development Center Category: Science and Technology and other Research and Development Funding Amount: $80,000 |
| Physics Frontiers Centers Apply for 22 592 Funding Number: 22 592 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Early Stage Innovations (ESI22) Apply for 80HQTR22NOA01 22ESI B2 Funding Number: 80HQTR22NOA01 22ESI B2 Agency: National Aeronautics and Space Administration, NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: $650,000 |
| Assistive Technology Act National Activities: State Training and Technical Assistance for Assistive Technology Programs and National Assistive Technology Public Internet Site Apply for HHS 2022 ACL CIP ATTA 0053 Funding Number: HHS 2022 ACL CIP ATTA 0053 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $625,000 |
| Assistive Technology Alternative Financing Program Apply for HHS 2022 ACL CIP ATTF 0055 Funding Number: HHS 2022 ACL CIP ATTF 0055 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $700,000 |
| DoD Multiple Sclerosis, Clinical Trial Award Apply for W81XWH 22 MSRP CTA Funding Number: W81XWH 22 MSRP CTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Multiple Sclerosis, Early Investigator Research Award Apply for W81XWH 22 MSRP EIRA Funding Number: W81XWH 22 MSRP EIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Multiple Sclerosis, Investigator-Initiated Research Award Apply for W81XWH 22 MSRP IIRA Funding Number: W81XWH 22 MSRP IIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Multiple Sclerosis, Exploration-Hypothesis Development Award Apply for W81XWH 22 MSRP EHDA Funding Number: W81XWH 22 MSRP EHDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| CWMD: Academic Research Initiative (ARI) Apply for WD ARI 22 001 Funding Number: WD ARI 22 001 Agency: Department of Homeland Security, Office of Procurement Operations - Grants Division Category: Science and Technology and other Research and Development Funding Amount: $300,000 |
| CWMD: Academic Research Initiative (ARI) Apply for DHS 22 CWMD 077 001 Funding Number: DHS 22 CWMD 077 001 Agency: Department of Homeland Security, Office of Procurement Operations - Grants Division Category: Science and Technology and other Research and Development Funding Amount: $300,000 |
| Natural Resources & Threatened Endangered Species Mgmt US Army Garrison Hawaii Oahu Apply for W9126G22 2 SOI 3024 Funding Number: W9126G22 2 SOI 3024 Agency: Department of Defense, Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $30,000,000 |
| Disaster Resilience Research Grants Apply for 22 593 Funding Number: 22 593 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $400,000 |
| Leading Engineering for America's Prosperity, Health, and Infrastructure Apply for 22 594 Funding Number: 22 594 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $2,000,000 |
| FY22 DEFENSE ESTABLISHED PROGRAM TO STIMULATE COMPETITIVE RESEARCH (DEPSCoR) – RESEARCH COLLABORATION (RC) Apply for FOA AFRL AFOSR 2022 0006 Funding Number: FOA AFRL AFOSR 2022 0006 Agency: Department of Defense, Air Force Office of Scientific Research Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| DOD Bone Marrow Failure Investigator-Initiated Research Award Apply for W81XWH 22 BMFRP IIRA Funding Number: W81XWH 22 BMFRP IIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 22 PCARP TRPA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.